S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities

Revolution Medicines (RVMD) Stock Price, News & Analysis

$34.92
-0.91 (-2.54%)
(As of 04/19/2024 ET)
Today's Range
$34.23
$36.37
50-Day Range
$29.00
$37.41
52-Week Range
$15.44
$38.73
Volume
1.24 million shs
Average Volume
1.25 million shs
Market Capitalization
$5.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.20

Revolution Medicines MarketRank™ Stock Analysis

Analyst Rating
Buy
3.10 Rating Score
Upside/​Downside
18.0% Upside
$41.20 Price Target
Short Interest
Healthy
7.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.68mentions of Revolution Medicines in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$671,249 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.18) to ($3.40) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.31 out of 5 stars

Medical Sector

139th out of 912 stocks

Biological Products, Except Diagnostic Industry

15th out of 150 stocks

RVMD stock logo

About Revolution Medicines Stock (NASDAQ:RVMD)

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

RVMD Stock Price History

RVMD Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Revolution Medicines (NASDAQ:RVMD) Shares Gap Up to $32.99
RVMD Apr 2024 36.000 call
See More Headlines
Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
4/20/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:RVMD
Fax
N/A
Employees
378
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.20
High Stock Price Target
$48.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+18.0%
Consensus Rating
Buy
Rating Score (0-4)
3.10
Research Coverage
10 Analysts

Profitability

Net Income
$-436,370,000.00
Pretax Margin
-3,798.71%

Debt

Sales & Book Value

Annual Sales
$11.58 million
Book Value
$11.09 per share

Miscellaneous

Free Float
150,691,000
Market Cap
$5.75 billion
Optionable
Optionable
Beta
1.54
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives


RVMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Revolution Medicines stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last twelve months. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RVMD shares.
View RVMD analyst ratings
or view top-rated stocks.

What is Revolution Medicines' stock price target for 2024?

10 analysts have issued 12-month price targets for Revolution Medicines' stock. Their RVMD share price targets range from $28.00 to $48.00. On average, they expect the company's share price to reach $41.20 in the next twelve months. This suggests a possible upside of 18.0% from the stock's current price.
View analysts price targets for RVMD
or view top-rated stocks among Wall Street analysts.

How have RVMD shares performed in 2024?

Revolution Medicines' stock was trading at $28.68 at the beginning of 2024. Since then, RVMD shares have increased by 21.8% and is now trading at $34.92.
View the best growth stocks for 2024 here
.

Are investors shorting Revolution Medicines?

Revolution Medicines saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 12,000,000 shares, a decrease of 26.8% from the March 15th total of 16,400,000 shares. Based on an average daily volume of 1,350,000 shares, the short-interest ratio is presently 8.9 days.
View Revolution Medicines' Short Interest
.

When is Revolution Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our RVMD earnings forecast
.

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) posted its earnings results on Monday, February, 26th. The company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by $0.29. The firm had revenue of $0.74 million for the quarter, compared to the consensus estimate of $1.20 million. Revolution Medicines's quarterly revenue was down 95.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.63) earnings per share.

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

When did Revolution Medicines IPO?

Revolution Medicines (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Who are Revolution Medicines' major shareholders?

Revolution Medicines' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Mass General Brigham Inc (0.21%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Sushil Patel, Thilo Schroeder and Xiaolin Wang.
View institutional ownership trends
.

How do I buy shares of Revolution Medicines?

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RVMD) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners